SARS-CoV-2 and influenza co-infection throughout the COVID-19 pandemic: An assessment of co-infection rates and cohort characterization

Tracking temporal and geographic trends in SARS-CoV-2 and influenza co-infection-related hospitalizations in the United States

In order to track temporal trends in SARS-CoV-2, influenza, and co-infection-related hospitalizations in the United States over the course of the pandemic, we used the “COVID-19 Reported Patient Impact and Hospital Capacity by Facility” dataset¹². The hospital population includes all hospitals registered with Centers for Medicare & Medicaid Services (CMS) as of June 1, 2020. For each reporting hospital, this dataset includes 7-day average case counts of hospitalized patients with PCR-confirmed COVID-19, PCR-confirmed influenza, and co-infections. We considered a subset of these hospitals with data available for these variables each week from October 30, 2020 to January 13, 2022. In addition, we filtered out hospitals with inconsistent data (e.g. more co-infection hospitalized cases than total influenza hospitalized cases for a single week) to obtain a final set of 3,003 hospitals for analysis. Since case counts less than 4 individuals are censored in this dataset, we imputed these values to be 1 for the computation of averages. For each week, we summed the average case counts across all 3,003 hospitals to obtain estimates for the average number of hospitalized patients with SARS-CoV-2, influenza, and co-infections at these facilities during that week.

To track geographic trends in SARS-CoV-2, influenza, and co-infection-related hospitalizations in the United States over the course of the pandemic, we used the “COVID-19 Reported Patient Impact and Hospital Capacity by State Timeseries” dataset¹³. This is similar to the above dataset except the data is aggregated at the state level, and case counts for facilities with fewer than 4 individuals are not censored for the sums. For each state on a map, we show the total number of patients hospitalized with laboratory-confirmed COVID-19 and influenza co-infections across all of the reporting facilities on January 15, 2022. In addition, for each state we compute the percentage of COVID-19 and influenza co-infections as the total number of hospitalized patients with co-infections divided by the total number of patients hospitalized with COVID-19.

Mayo Clinic Institutional Review Board

We performed a retrospective analysis on electronic health record (EHR) data from the Mayo Clinic under the IRB #20-003278 “Study of COVID-19 patient characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic and operational decisions.” This includes all individuals with research authorization on file who received a PCR test for SARS-CoV-2 at Mayo Clinic sites since January 1, 2020. The Mayo Clinic Enterprise is a multi-state academic medical center with major campuses in Rochester, MN, Jacksonville, FL, and Scottsdale, AZ, along with additional satellite sites in other states including Iowa and Wisconsin.

Cohort definitions

The study population included all individuals who have received a positive PCR test for SARS-CoV-2 at the Mayo Clinic between January 1, 2020 and January 17, 2022. From this study population, we constructed the following cohorts: (1) “Overall COVID-19”: all individuals with a positive PCR test for SARS-CoV-2, (2) “COVID-19 + Flu”: all individuals with a positive PCR test for SARS-CoV-2 along with a diagnosis of influenza within 14 days.

By definition, all individuals in the study population were included in the “Overall COVID-19” cohort. In addition, some individuals in the study population were included multiple times in this cohort if they had multiple positive PCR tests for SARS-CoV-2 during the study period spaced at least 90 days apart. For each individual, the date of the first positive PCR test was considered to be the primary infection, and the date of each subsequent positive PCR test spaced at least 90 days apart was considered to be a re-infection.

To construct the “COVID-19 + Flu” cohort, we used a combination of data sources from within Mayo Clinic Enterprise to determine influenza diagnosis: laboratory tests (Table S1), diagnostic billing codes (Table S2), and unstructured clinical notes. Cases without a laboratory correlate were manually reviewed to confirm influenza diagnosis. If any of these data sources indicated that an individual in the “Overall COVID-19” cohort had an influenza diagnosis within +/-14 days of their PCR test date, then this individual was included in the “COVID-19 + Flu” cohort. If there was conflicting information across the data types, i.e. there was a negative influenza lab test result within +/-7 days of a diagnostic billing code or diagnosis based on the notes, this was not considered to be a case of co-infection. Similar to the “Overall COVID-19” cohort, individuals may be included multiple times in the “COVID-19 + Flu” cohort if they had multiple co-occurrences of SARS-CoV-2 and influenza infection. The methodology to determine influenza diagnoses from the unstructured clinical notes is described below.

Augmented curation to determine influenza diagnosis from clinical notes

We used a BERT-based neural network model¹⁴ to extract the sentiment of all mentions of influenza in the clinical notes for the study population. This phenotype sentiment model has been previously applied to determine signs and symptoms of COVID-19 from unstructured clinical notes with an out-of-sample accuracy of 93.6% and precision/recall values above 95%⁸. For each occurrence of a phenotype in a clinical note, the model outputs one of the following labels: “Yes”: confirmed diagnosis of the phenotype, “Maybe”: uncertain/differential diagnosis of the phenotype, “No”: ruled-out diagnosis of the phenotype, or “Other”: all other mentions of the phenotype (e.g. family history). For this application, we considered the following terms as synonyms for influenza: “influenza”, “influenza A”, “influenza B”, “influenza A/B”, “influenza virus”, “flu”, “avian flu”, “H1N1”, “H5N1”, “H3N2”, and “H7N9”. Individuals with at least one clinical note labeled “Yes” by the model with ≥ 90% confidence within +/-14 days of their positive PCR test were counted as positive for influenza and included in the “COVID-19 + Flu” cohort. Cases without laboratory correlates were manually reviewed and confirmed for inclusion.

Curation of clinical covariates from structured EHR data

For each cohort, we curated clinical covariates from the structured EHR data with features including: demographics (age, sex, race, ethnicity), geographic location and time of PCR test, COVID-19 vaccination status, influenza vaccination status, and comorbidities, and 30-day clinical outcomes including: hospitalization, ICU admission, and mortality. For each individual case in each cohort, we considered the date of the positive PCR test for SARS-CoV-2 to be the index date (day = 0) to define the clinical covariates. To classify the geographic location of PCR testing, we used the following Mayo Clinic regions: Mayo Clinic - Arizona (includes PCR tests administered at the major campus in Scottsdale, AZ), Mayo Clinic - Florida (includes PCR tests administered at the major campus in Jacksonville, FL), and Mayo Clinic - Midwest (includes PCR tests administered at the major campus in Rochester, MN as well as surrounding Mayo Clinic Health Systems sites in Minnesota, Wisconsin, and Iowa).

To determine COVID-19 vaccination status, we considered the following FDA-authorized vaccines: Janssen (Ad26.COV2.S), Moderna (mRNA-1273), and Pfizer/BioNTech (BNT162b2). The categories for COVID-19 vaccination status were defined as: “Unvaccinated”: individuals who do not have an FDA-authorized COVID-19 vaccine on record, “Partial”: individuals who have received exactly 1 dose of either BNT162b2 or mRNA-1273, “Full”: individuals who have received exactly 1 dose of Ad26.COV2.S or exactly 2 doses of either BNT162b2 or mRNA-1273 at least 14 days prior to their PCR date, and “Boosted”: individuals who are fully vaccinated and have received an additional dose of either Ad26.COV2.S, BNT162b2, or mRNA-1273 at least 14 days prior to their PCR date. For each individual case, vaccination status is determined at the time of the associated positive PCR test, so it is possible that some individuals who are fully vaccinated now may be considered unvaccinated on their index dates. To determine influenza vaccination status, we checked if the individual received an influenza vaccine at least 14 days prior to their positive PCR test for SARS-CoV-2 within the current flu season beginning on August 1st. For example, an individual with a positive PCR test on October 15, 2021 would need to have received a flu vaccine between August 1, 2021 and October 1, 2021 in order to be considered vaccinated for the flu season. In Table S3, we provide a comprehensive list of the influenza vaccines considered.

We considered the following time periods of PCR testing dates: March 12, 2020 to March 15, 2021; March 16, 2021 to June 15, 2021; June 16, 2021 to December 13, 2021; and December 14, 2021 onwards. These time periods roughly correspond to the time periods when the SARS-CoV-2 strains Wuhan (original), Alpha, Delta, and Omicron were the dominant strains in the United States over the course of the study.

To determine the comorbidities for each cohort, we considered all 31 disease categories in the Elixhauser comorbidity index¹⁵, including: congestive heart failure, cardiac arrhythmia, valvular disease, pulmonary circulation disorder, peripheral vascular disorder, hypertension (uncomplicated), hypertension (complicated), paralysis, other neurological disorder, chronic pulmonary disease, diabetes (uncomplicated), diabetes (complicated), hypothyroidism, renal failure, liver disease, peptic ulcer disease (excluding bleeding), AIDS / HIV, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid arthritis, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psychoses, and depression. For each disease category, individuals with an associated ICD-10 code within the past 5 years prior to their positive PCR testing date were counted as positive for the phenotype. For each individual, a single Elixhauser Comorbidity Index score was calculated using the Van Walraven method¹⁶.

SARS-CoV-2 variant prevalence from the NCBI Virus database

We used the NCBI Virus database⁶ to determine the prevalence of the different SARS-CoV-2 variants over time. This dataset allows us to find the times of dominance for each variant and evaluate the most likely SARS-CoV-2 variant contributing to co-infection cases.

From the NCBI Virus database, we retrieved 3,483,717 SARS-CoV-2 genome samples from human hosts in the United States which were collected from January 1, 2020 to January 15, 2022 and span 1,385 PANGO lineages. We categorized the samples as an Alpha, Beta, Delta, Gamma, or Omicron variant using the variant classification information from the CDC to map the PANGO lineages to particular variants.¹⁷ We found the prevalence of the variants on each day in our study period by normalizing the daily variant sample count by the daily total sample count in the NCBI Virus dataset. In addition, we used this dataset to determine the dates at which a new variant became the dominant strain in the United States (i.e. the first date that Alpha was more prevalent than the ancestral lineage and the first date that Delta was more prevalent than Alpha).

Influenza strain prevalence from the CDC FluView database

Similarly, we used the CDC FluView database⁷ to determine the prevalences of the two main influenza strains (A(H1N1)pdm09 and A(H3N2)) over time. This database provides the number of influenza strain types of all those sampled from sites in the United States on a weekly basis. From this database, we retrieved 38,052 influenza samples with known subtyping from January 1, 2020 to January 15, 2022. The 6 strains considered were A(H3N2v), A(H1N1)pdm09, A(H3N2), B, BVIC, BYAM. We computed the prevalence of the strains for each week in our study period as the weekly strain sample count divided by the weekly total subtype sample count.

Estimates of COVID-19 and influenza co-infection prevalences

To estimate the prevalence of reported COVID-19 and influenza co-infections, we divided the number of reported COVID-19 and influenza cases by the total number of COVID-19 cases observed in the Mayo Clinic EHR database. In addition, to estimate the total (reported + unreported) prevalence of COVID-19 and influenza co-infections, we divided the number of observed COVID-19 and influenza co-infections (from lab tests only) by the number of COVID-19 cases with lab tests for influenza available. Finally, to estimate the prevalence of COVID-19 co-infections among all influenza cases, we divided the number of reported COVID-19 and influenza cases by the total number of influenza cases observed during the study period. For each estimate, 95% confidence intervals using Wilson’s score method¹⁸ are reported, which were computed using the “stats” package (version 4.1.2) in R.

Estimates of the expected number of co-infection cases

For each of the study time periods, we estimated the expected number of COVID-19 and influenza co-infection cases based upon the background incidence rates of COVID-19 and influenza at the Mayo Clinic. We considered all cases at the Mayo Clinic during each study time period with PCR testing data available for both COVID-19 and influenza within +/- 14 days, including both positive and negative PCR tests. We considered the same time periods as described above: March 12, 2020 to March 15, 2021; March 16, 2021 to June 15, 2021; June 16, 2021 to December 13, 2021; and December 14, 2021 onwards. For each case, the date of the SARS-CoV-2 PCR test was used to determine the time period.

For each time period, we estimated the probability of COVID-19 among the co-tested population as the number of co-tested cases with positive PCR tests for SARS-CoV-2 divided by the total number of co-tested cases. Similarly, we estimated the probability of Influenza among the co-tested population as the number of co-tested cases with positive PCR tests for Influenza divided by the total number of co-tested cases. We compute the expected number of COVID-19 and Influenza cases for the time period as follows: where:

n_co-tested: Total number of co-tested cases during the time period,

Pr(COVID-19+ | Co-Tested): Probability of COVID-19 among co-tested population for the time period,

Pr(Flu+ | Co-Tested): Probability of influenza among the co-tested population for the time period, c: Estimated model parameter.

In the above estimate, the main assumption is that the probabilities of testing positive for COVID-19 and influenza are independent in the general population. In addition, we assume that the estimated model parameter c is constant over the course of the study. For these estimates of expected co-infection cases, we compute 95% confidence intervals using the Delta method¹⁹. In the following section, we provide a detailed description of the probability model underlying this formula along with a description of the method used to estimate the model parameter c.

Probability model used to estimate the expected number of co-infection cases

In this section, we provide a description of the probability model which is used to estimate the expected number of COVID-19 and influenza co-infection cases at the Mayo Clinic. The primary assumption of this model is that the probabilities of testing positive for COVID-19 and influenza are independent in the general population of patients at the Mayo Clinic. For example, if the background prevalences of COVID-19 and influenza in the general population were 1% and 0.2% respectively, then we would expect the prevalence of co-infections to be 1% * 0.2% = 0.002%.

For each individual case, we define the index date to be the date of the SARS-CoV-2 PCR test. We define the following probability events:

COVID-19+: The individual received a positive PCR test for COVID-19 within +/- 14 days of the index date,

Flu+: The individual received a positive PCR test for influenza within +/- 14 days of the index date, and

Co-Tested: The individual received PCR tests for both COVID-19 and influenza within +/- 14 days of the index date.

Given these events, we define the following probabilities of COVID-19 and influenza mono-infections:

Pr(COVID-19+): Probability that the individual received a positive PCR test for COVID-19 within +/- 14 days of the index date (among patients with and without PCR testing),

Pr(COVID-19+ | Flu+): Probability that the individual received a positive PCR test for COVID-19 within +/- 14 days of the index date (among patients with positive PCR tests for influenza),

Pr(COVID-19+ | Co-Tested): Probability that the individual received a positive PCR test for COVID-19 within +/- 14 days of the index date (among patients with PCR tests available for both influenza and COVID-19),

Pr(COVID-19+ | Flu+, Co-Tested): Probability that the individual received a positive PCR test for COVID-19 within +/- 14 days of the index date (among patients with a positive PCR test result for influenza and a COVID-19 PCR test result available).

Pr(Flu+): Probability that the individual received a positive PCR test for influenza within +/- 14 days of the index date (among patients with and without PCR testing),

Pr(Flu+ | COVID-19+): Probability that the individual received a positive PCR test for influenza within +/- 14 days of the index date (among patients with positive PCR tests for COVID-19),

Pr(Flu+ | Co-Tested): Probability that the individual received a positive PCR test for influenza within +/- 14 days of the index date (among patients with PCR tests available for both influenza and COVID-19).

Pr(Flu+ | COVID-19+, Co-Tested): Probability that the individual received a positive PCR test for influenza within +/- 14 days of the index date (among patients with a positive PCR test result for COVID-19 and an influenza PCR test result available).

From the independence assumption, it follows that:

In addition, we define the following probabilities of COVID-19 and influenza co-infections:

Pr(COVID-19+, Flu+): Probability that the individual received positive PCR tests for both COVID-19 and influenza within +/- 14 days of the index date (among patients with and without PCR testing),

Pr(COVID-19+, Flu+ | Co-Tested): Probability that the individual received positive PCR tests for both COVID-19 and influenza within +/- 14 days of the index date (among patients with PCR tests available for both influenza and COVID-19).

Similarly, we define the following probabilities that PCR co-testing data is available:

Pr(Co-Tested): Probability that the individual received PCR tests for both COVID-19 and influenza within +/- 14 days of the index date

Pr(Co-Tested | COVID-19+): Probability that the individual received PCR tests for both COVID-19 and influenza within +/- 14 days of the index date (among patients with a positive PCR test result for COVID-19),

Pr(Co-Tested | Flu+): Probability that the individual received PCR tests for both COVID-19 and influenza within +/- 14 days of the index date (among patients with a positive PCR test result for influenza),

Pr(Co-Tested | COVID-19+, Flu+): Probability that the individual received PCR tests for both COVID-19 and influenza within +/- 14 days of the index date (among patients with a positive PCR test results for both COVID-19 and influenza).

By definition, because all patients who have received positive PCR tests for both COVID-19 and influenza have received at least 1 PCR test of each type.

Let n_co-tested be the total number of individuals with PCR testing data available for both COVID-19 and influenza within +/- 14 days of the index date. Given these probabilities, we estimate the expected number of co-infection cases at the Mayo Clinic as: where:

We can interpret this model parameter c as the ratio of co-testing PCR rates in the general population relative to the co-testing PCR rates in the COVID-19 and influenza positive populations. Substituting in the actual number of observed COVID-19 and influenza co-infection cases over the study period, we can solve for this model parameter c as: where:

n_coinfection: number of co-infected cases,

n_covid: number of cases with positive PCR tests for COVID-19, and

n_flu: number of cases with positive PCR tests for influenza.

In order to estimate the expected number of co-infected cases for a particular time period t (e.g. from December 13, 2021 onwards), we used the same expected value formula as above with this estimated value for c: where: n_{co-tested, t}, Pr_t(COVID-19+ | Co-Tested), and Pr_t(Flu+ | Co-Tested) are time period-specific case counts and probability estimates.

Statistical analysis

To identify clinical covariates enriched in the co-infected cohort with respect to the overall COVID-19 cohort, we report relative risk estimates for each of the categorical variables in the dataset, including: demographics, (sex, race, ethnicity), geographic location and time of PCR test, COVID-19 and influenza vaccination status, and comorbidities. For each covariate, the relative risk was computed as the rate in the co-infected cohort divided by the rate in the control cohort. In addition, we report 95% confidence intervals using the Delta method approximation¹⁹. Relative risks and 95% confidence intervals were computed using the “scipy” package (version 1.7.2) in Python.

Recent surges in COVID-19 and influenza cases correspond with recent rises in the number of hospitalized patients with COVID-19 infection, influenza infection, and co-infections in the United States

In Figure 1, we show trends in COVID-19 and influenza infections, hospitalizations, and co-infection-related hospitalizations across the United States, aggregated from the CDC COVID Data Tracker, CDC FluView, and HHS Protect Public Data Hub. We observe that COVID-19 infection rates have risen to all time highs during the Omicron era (Figure 1A), while influenza infection rates have been negligible throughout the pandemic until recently at the beginning of the 2021-2022 flu season (Figure 1B). Although we are unable to observe co-infection rates in the overall US population, we can observe co-infection rates among hospitalized patients from HHS Protect data. In Figures 1C and 1D, we show the average number of hospitalized patients with COVID-19 infection, influenza infection, and co-infections for 3,003 hospitals with data reporting to HHS Protect. We observe large peaks in hospitalized COVID-19 patients during the Original (Wuhan), Delta, and Omicron waves of the pandemic (Figure 1C). On the other hand, we observe that hospitalized influenza case counts were slightly elevated during the 2020-2021 flu season but have dramatically increased starting in October 2021 (Figure 1D). Case counts of hospitalized co-infected patients follow a similar trend, with a slight elevation during the 2020-2021 flu season and rising case counts observed from December 2021 to January 2022 (Figure 1D).

• Download figure
• Open in new tab

Figure 1: Case counts and hospitalizations for COVID-19, influenza, and co-infections in the United States.

In panel (A), we show weekly case counts of new COVID-19 infections in the US reported by the CDC COVID Data Tracker. In panel (B), we show weekly case counts of new influenza infections in the US reported by CDC FluView. In panels (C) and (D), we show trends in hospitalized cases of COVID-19, Influenza, and co-infections over time for 3,003 hospitals in the U.S. which have submitted records to the HHS Protect Public Data Hub since the last week in October 2020 (see Methods). In panel (C), we show COVID-19 hospitalized case counts, and in panel (D) we show influenza and co-infection hospitalized case counts. In each of the plots, we shade the periods of time corresponding to the different waves of the pandemic, including Alpha (March 16, 2021 - June 15, 2021; blue), Delta (June 16, 2021 - December 13, 2021; green), and Omicron (December 14, 2021 - January 17, 2022; purple).

The recent rise in hospitalized co-infection cases corresponds with the Omicron SARS-CoV-2 and H3N2 influenza strains

In the plots for Figure 1, we highlighted the time periods corresponding to different waves of the COVID-19 pandemic, including time periods when the Alpha, Delta, and Omicron variants were the most prevalent SARS-CoV-2 strains. Next, we provide a more granular view of the SARS-CoV-2 and influenza strains estimated to be in circulation in the United States over the course of the pandemic. In Figure 2, we provide the estimated percentages of individual SARS-CoV-2 and influenza strains sequenced in the United States based on the NCBI Virus and CDC FluVew databases, with SARS-CoV-2 strains including Alpha, Beta, Delta, Gamma, and Omicron, and influenza strains including H1N1 and H3N2. Taken in combination with the HHS Protect data, we observe that the recent rise in COVID-19 and influenza co-infection-related hospitalizations has occurred while the Omicron SARS-CoV-2 variant and the H3N2 influenza variant were most prevalent in the United States.

• Download figure
• Open in new tab

Figure 2: Trends of SARS-CoV-2 and influenza strain prevalences in the United States over time.

In panel (A), we show SARS-CoV-2 strain percentages in the US from NCBI data, including the following strains: Alpha (blue), Beta (orange), Delta (green), Gamma (red), and Omicron (purple). In this plot, prevalence of the original (Wuhan) strain is not shown. In panel (B), we show influenza strain percentages in the US from CDC FluView data, including the following strains: A(H1N1)pdm09 (gray) and A(H3N2) (pink). In both panels (A) and (B), less common strains are omitted from the plots so the strain percentages do not necessarily add up to 100% each day.

Hospitalized co-infection cases have been observed at low rates across the United States

In Figure 3, we show the geographic distribution of hospitalized COVID-19 and influenza cases in the United States on January 27, 2022 based on data from the HHS Protect Public Data Hub. We observe that the states with the highest numbers of hospitalized co-infection cases are Georgia (35 cases), Alabama (24 cases), and Texas (22 cases) (Figure 3). Alabama and Georgia have the highest percentage of hospitalized COVID-19 patients with influenza co-infections, but these percentages are still low (Alabama: 0.8% of hospitalized COVID-19 cases, Georgia: 0.7% of hospitalized COVID-19 cases). There are no states in which co-infections comprise over 1% of all COVID-19 hospitalized cases.

• Download figure
• Open in new tab

Figure 3: Geographic data on COVID-19 and influenza co-infections from HHS Protect Public Data Hub.

We show the geographic distribution of hospitalized co-infection cases in the United States. The top map shows the states colored by total number of co-infection cases, and the bottom map shows the states colored by co-infection percentage. For each state, the co-infection percentage is calculated as the number of hospitalized co-infection cases divided by the total number of hospitalized COVID-19 cases.

The recent surge in co-infection cases observed at the Mayo Clinic coincides with recent surges in both COVID-19 and influenza cases observed at the health system

EHR data from Mayo Clinic corroborates the observed trend in the public data that co-infection cases are rising in step with rises in COVID-19 and influenza (Figure 4). Co-infection cases were defined based on features in the EHR data as described in the methodology and summarized in Figure 4A. New cases of COVID-19 and influenza at Mayo Clinic (Figures 4B and 4C) follow similar trends to those seen on the national level (Figures 1A and 1B), and co-infection cases at Mayo Clinic coincide with the rise in the COVID-19 and influenza cases at the hospital system. In Table S4, we provide case counts of COVID-19 infections, influenza infections, and co-infections observed at the Mayo Clinic during each of the four study time periods (corresponding to the Wuhan (original), Alpha, Delta, and Omicron waves).

• Download figure
• Open in new tab

Figure 4: Schematic of cohort definitions and daily case counts of COVID-19 infection, influenza infection, and co-infections at the Mayo Clinic.

In panel (A), we provide the inclusion criteria of COVID-19 and co-infection cohorts based on the Mayo Clinic EHR data and the resulting cohort sizes. In panels (B) and (C), we show counts of COVID-19 cases and influenza cases, respectively. In panel (D), we show counts of COVID-19 and influenza co-infection cases including 73 cases determined via PCR testing, ICD codes, and/or clinical notes. Note that the y-axis ranges in each plot are different, and the case counts for COVID-19 infection are significantly greater than the case counts for influenza infection which are in turn significantly greater than the case counts for COVID-19 and influenza co-infection.

Laboratory testing for COVID-19 and influenza co-infections is low and confirmed co-infections are rare

Among 171,639 COVID-19 cases at the Mayo Clinic, only 10,431 (6.1%) cases had an influenza PCR test recorded within two weeks of their positive SARS-CoV-2 PCR test (Table 1). Of these 10,431 cases, only 63 individuals tested positive for influenza, resulting in an estimated co-infection prevalence of 0.604% (95% CI: [0.472%, 0.772%]). Given the possibility of incomplete lab data in the EHR, we also considered other documentation methods of influenza diagnosis, which increased the size of the co-infected cohort to 73 cases (3 additional cases determined from ICD codes, 7 additional cases determined from augmented curation of clinical notes). In the overall COVID-19 population (n = 171,639), the prevalence estimate of influenza co-infection from all three of these data sources is 0.043% (95% CI: [0.034%, 0.053%]) (Table 1). Among the population with PCR-confirmed influenza during the study period (n = 2,175), the prevalence of COVID-19 co-infection was 2.90% [2.27%, 3.69%] (Table 1).

Co-infection with SARS-CoV-2 and influenza is not more frequent than expected by chance

We next asked whether co-infections have occurred at unexpectedly high rates during various intervals throughout the pandemic, given the background rates of COVID-19 and influenza. For each time period analyzed, the observed co-infection case counts fall within or slightly below the 95% confidence intervals of the expected co-infection case counts (Table 2). In particular, during the Omicron era (from December 14, 2021 to January 17, 2022), the expected number of COVID-19 and influenza co-infection cases among this population was 80.9 cases (95% CI: [76.6, 85.1]), while the observed count was only 54 cases. During the Delta era (from June 16, 2021 to December 2021), the expected number of co-infection cases in this population was 13.9 (95% CI: [12.7, 15.2]), but only 9 co-infection cases were observed. These results suggest that after controlling for the background rates of both COVID-19 and influenza, the number of co-infections is not higher than expected by chance.

COVID-19 and influenza co-infections are associated with time and location of PCR test, re-infections, COVID-19 vaccine status, COVID-19 vaccine type, age, and sex

We next compared the clinical characteristics of the overall COVID-19 cohort (n = 171,639 cases) and the co-infected cohort (n = 73 cases) (Table 3). The co-infected cohort was younger on average, with a mean age of 28.4 years old (std dev: 21.7 years) compared to 39.8 years old (std dev: 20.9 years) for the overall COVID-19 cohort. In addition, co-infections were more prevalent among men compared to women (RR: 1.3, 95% CI: [1.1, 1.5]). Other clinical covariates such as race, ethnicity, and pre-existing conditions were similar between the two cohorts (Table 3). As expected, most co-infection cases (n = 55, 75.3%) occurred during the Omicron era (December 14, 2021 - January 17, 2022). Compared to the overall COVID-19 cohort, co-infection cases were more likely to be COVID-19 re-infections (RR: 2.2, 95% CI: [1.0, 6.0]) and to occur in individuals who were partially vaccinated (RR: 2.6, 95% CI: [1.3, 6.2]) or vaccinated with the Moderna COVID-19 vaccine (RR: 2.1, 95% CI: [1.2, 4.2]) (Table 3). We also observed that co-infection cases were slightly higher in the Mayo Clinic - Midwest region compared to the other regions (RR: 1.1, 95% CI: [1.0, 1.2]).